Search results
Results from the WOW.Com Content Network
Rifampicin can reduce the efficacy of birth control pills or other hormonal contraception by its induction of the cytochrome P450 system, to the extent that unintended pregnancies have occurred in women who use oral contraceptives and took rifampicin even for very short courses (for example, as prophylaxis against exposure to bacterial meningitis).
Lepetit introduced Rifampicin, an orally active rifamycin, in 1966. [16] Rifabutin, a derivative of rifamycin S, was invented by Italian drug manufacturer Achifar in 1975 and came onto the US market in 1992. [16] Hoechst Marion Roussel (now part of Aventis) introduced rifapentine to the US market in 1998, with Achifar having synthesized it in ...
A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. [1] Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.
Over a 45-year span — between 1975 and 2020 — improvements in cancer screenings and prevention strategies have reduced deaths from five common cancers more than any advances in treatments.
Dapsone is commonly used in combination with rifampicin and clofazimine for the treatment of leprosy. [3] It is also used to both treat and prevent pneumocystis pneumonia (PCP). [ 3 ] [ 9 ] It is also used for toxoplasmosis in people unable to tolerate trimethoprim with sulfamethoxazole .
Whether inflammation is present in the body before or after a cancer diagnosis, it affects all life stages of cancer—part of what Ravella calls the “tumor microenvironment” — “from the ...
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin.